Galcanezumab for preventing cluster headache [ID1212]
Discontinued
Reference number: GID-TA10425
The Department for Health and Social Care has asked NICE to conduct an appraisal of Galcanezumab for preventing episodic cluster headache.
However, the company have advised that The European Medicines Agency Committee for Medicinal Products (CHMP) have issued a negative opinion for galcanezumab injection for the preventive treatment of episodic cluster headache in adults in the European Union. Therefore, NICE has decided to suspend this appraisal on its work programme.
As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.